Polar Asset Management Partners Inc. Purchases 3,000 Shares of Repligen Co. (NASDAQ:RGEN)

Polar Asset Management Partners Inc. lifted its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 76.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,900 shares of the biotechnology company's stock after purchasing an additional 3,000 shares during the period. Polar Asset Management Partners Inc.'s holdings in Repligen were worth $993,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. Signaturefd LLC grew its position in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares in the last quarter. Sava Infond d.o.o. acquired a new stake in Repligen during the fourth quarter worth approximately $29,000. Raiffeisen Bank International AG acquired a new stake in Repligen during the fourth quarter worth approximately $29,000. Itau Unibanco Holding S.A. acquired a new stake in Repligen during the fourth quarter worth approximately $40,000. Finally, Global Retirement Partners LLC grew its position in Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after buying an additional 129 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Repligen Price Performance

Shares of RGEN traded down $4.66 during trading hours on Friday, reaching $117.66. The stock had a trading volume of 1,145,832 shares, compared to its average volume of 743,182. Repligen Co. has a 12 month low of $102.97 and a 12 month high of $182.52. The stock has a market capitalization of $6.61 billion, a PE ratio of -230.71, a PEG ratio of 4.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company's 50-day moving average is $128.09 and its two-hundred day moving average is $143.65.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Repligen's revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.28 EPS. Research analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. TD Cowen initiated coverage on Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 target price on the stock. Evercore ISI initiated coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 target price on the stock. Royal Bank of Canada reduced their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Finally, Wall Street Zen raised Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Repligen has an average rating of "Moderate Buy" and an average target price of $173.25.

Insider Buying and Selling

In related news, Director Margaret Pax purchased 250 shares of the business's stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.